Merck’s VIGOR study used 8,000 subjects. Notably, Merck chose to include only subjects whose risk of experiencing a heart attack was low. Half the subjects in the study received Vioxx, and the other half received naproxen. Of those receiving Vioxx, 20 had heart attacks. Of those receiving naproxen, four had heart attacks. Many medical researchers believe that naproxen does not reduce the incidence of heart attacks. Suppose that this is the case. From the vantage point of 1999, discuss whether the study outcome was just a fluke, with Vioxx actually being no riskier than naproxen when it comes to heart attacks.